Jounce Therapeutics Profile

21.76
USD 2.29  11.76%
12.75
100%
21.76
19.27
71%
22.73

Jounce Therapeutics exotic insider transaction detected

Jounce Therapeutics Inc insider trading alert for general transaction of stock option (right to buy) by Cole Hugh M, Chief Business Officer, on December 21, 2017. This event was filed by Jounce Therapeutics Inc with SEC on 2017-12-21. Initial filing of beneficial ownership - SEC Form 3 [view details]   

Jounce Therapeutics Summary

Jounce Therapeutics Inc (JNCE) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS, U.S.A and employs 8 people. Jounce Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 556.56 M. Jounce Therapeutics Inc has 32.25 M outstanding shares of which 3.27 M shares are currently shorted by private and institutional investors with about 24.78 trading days to cover. The company currently holds about 251.09 M in cash with (78.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.8.
Check Jounce Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Jounce Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Jounce Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
40 
Chance of
Financial Distress (0 to 100%)
< 17% 
Equity ratings for Jounce Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Jounce Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameJounce Therapeutics Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
ExchangeBATS Exchange
CIK Number01640455.0
CUSIP481116101
IndustryPharmaceutical Products
BenchmarkDOW
CurrencyUSD - US Dollar

Recommendations

Jounce Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
30.0Strong Buy3Odds
Jounce Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Jounce Therapeutics Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Jounce Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.25November 8, 2017
Jounce Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate